Isec Healthcare Ltd · SGX:40T
Isec Healthcare — FY2019 Earnings Presentation
23 slides from Isec Healthcare's earnings presentation, Feb 26, 2020
Slide 1: Corporate Presentation
LOCAL FOCUS REGIONAL VISION Corporate Presentation 12 months ended 31 December 2019 Page 0
Slide 2: Sponsor disclaimer
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual
Slide 3: Table of Content
Table of Content Business Overview Competitive Strengths of the Group Business Strategies and Expansion Plans Corporate Developments and Use of Proceeds 12 Months Financial Highlights for the Period Ended 31 December 2019 Page 2
Slide 4: Business Overview
Business Overview Page 3
Slide 5: Business Overview
Business Overview • Specialised Health Services – Medical eye care service provider • ISEC is a comprehensive medical eye care service provider, with ambulatory surgical centres in Malaysia (Kuala Lumpur, Penang, Malacca & Sibu), provides specialist medical ophthalmology services to Asia Pacific Eye
Slide 6: Competitive Strengths of the Group
Competitive Strengths of the Group Page 5
Slide 7: Competitive Strengths of the Group
Business Overview Competitive Strengths of the Group 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well pos
Slide 8: Business Strategies and Expansion Plans
Business Strategies And Expansion Plans Page 7
Slide 9: Business Strategies
Business Strategies To reach out to more patients in locations where we currently operate, as well as new locations such as major Growing the ISEC cities or locations in Peninsular Malaysia, East Malaysia, Brand and Singapore and Myanmar Expanding into To expand via setting up of subsidiaries, joint
Slide 10: Expansion Plans
Expansion Plans Business expansion in the Asia Pacific region (including Malaysia, Singapore and Malaysia & Myanmar) Singapore Target Countries Page 9
Slide 11: Corporate Developments and Use of Proceeds
Corporate Developments And Use of Proceeds Page 10
Slide 12: Corporate Developments
Corporate Developments January 2020 – Proposed Acquisition of the Entire Issued and Paid-up Share Capital of Indah Specialist Eye Centre Sdn. Bhd. (“Indah Specialist”) Unless otherwise defined, capitalised terms used on pages 11, 12, 13 and 14 shall have the same meanings ascribed to them in the Com
Slide 13: Corporate Developments
Corporate Developments January 2020 – Proposed Acquisition of the Entire Issued and Paid-up Share Capital of Indah Specialist Eye Centre Sdn. Bhd. (Cont’d) Summary of the proposed acquisition (Cont’d) (iii) within 24 months after the date of Completion, the Company shall pay 10% of the Cash Portion;
Slide 14: Corporate Developments
Corporate Developments January 2020 – Proposed Acquisition of the Entire Issued and Paid-up Share Capital of Indah Specialist Eye Centre Sdn. Bhd. (Cont’d) Summary of the proposed acquisition (Cont’d) • Completion is subject to certain conditions precedent being satisfied or waived in accordance wit
Slide 15: Corporate Developments
Corporate Developments January 2020 – Proposed Acquisition of the Entire Issued and Paid-up Share Capital of Indah Specialist Eye Centre Sdn. Bhd. (Cont’d) Rationale for the proposed acquisition • Indah Specialist is expected to provide the Group with a growing stream of recurring income and cash fl
Slide 16: Use of Proceeds
Use of Proceeds As at 26 February 2020 Amount allocated pursuant to reallocation of Use of proceeds Amount allocated unutilised listing Amount S$’000 expenses utilised Balance S$’000 S$’000 S$’000 Business expansion in Asia Pacific region (including Malaysia and 13,800 300 (13,942) (N1) 158 Singapor
Slide 17: 12 Months Financial Highlights
12 Months Financial Highlights for the Period Ended 31 December 2019 Page 16
Slide 18: Revenue
Revenue SGD’mil FY2019 vs FY2018 The increase in Group revenue was mainly attributable to increased business activities from the Group’s specialised health services business segment. Page 17
Slide 19: Revenue – Malaysia
Revenue – Malaysia RM’mil SGD’mil 7.1% 8.7% Revenue from Malaysia operations in Ringgit Malaysia (“RM”) increased from RM92.8 million in FY2018 to RM100.9 million in FY2019, up 8.7% mainly due to increased business activities. Singapore Dollar translated revenue from Malaysia operations in FY2019 wa
Slide 20: EBITDA and Profit After Tax (PAT)
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and Profit After Tax (PAT) SGD’000 (1) 13.3% -2.9% (1) (1) Adjusted after adding back impairment loss for goodwill S$1.18 million. The variance in EBITDA was mainly due to the increased depreciation expenses by S$1.6 million and i
Slide 21: Cash Position
Cash Position Total cash and cash equivalents Unutilised IPO proceeds Cash balances SGD’mil Total cash and cash equivalents as at 31 December 2019 was S$25.7 million. No bank borrowings. Cash balances (excluding unutilised IPO proceeds) decreased from S$26.0 million as at 31 December 2018 to S$25.5
Slide 22: Statement of Financial Position
Statement of Financial Position S$’000 31 December 31 December 2019 2018 Key Assets Plant and equipment 3,957 3,735 Right-of-use assets 4,130# - Intangible assets 36,358^ 38,182^ Trade and other receivables 3,085 2,984 Cash and cash equivalents 25,657 27,105 Key Liabilities Lease liabilities – non-c
Slide 23: Thank You
Thank You Page 22